Jennison Associates LLC Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Jennison Associates LLC lowered its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 10.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,211,915 shares of the company’s stock after selling 135,037 shares during the quarter. Jennison Associates LLC owned approximately 1.19% of Dyne Therapeutics worth $28,553,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its holdings in Dyne Therapeutics by 11.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock worth $508,000 after purchasing an additional 2,265 shares during the period. KBC Group NV increased its position in Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Dyne Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company’s stock worth $3,655,000 after buying an additional 4,236 shares during the period. Virtue Capital Management LLC raised its stake in shares of Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock worth $834,000 after buying an additional 981 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock valued at $66,802,000 after buying an additional 84,760 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,071 shares of company stock worth $606,476 in the last three months. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $14.79 on Wednesday. The stock has a market capitalization of $1.51 billion, a PE ratio of -4.15 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1-year low of $13.23 and a 1-year high of $47.45. The business has a 50 day simple moving average of $21.84 and a two-hundred day simple moving average of $31.15.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on DYN shares. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Friday, January 10th. Royal Bank of Canada restated an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Robert W. Baird initiated coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. Finally, Chardan Capital restated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $49.91.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.